Imagine Owning Neuren Pharmaceuticals (ASX:NEU) While The Price Tanked 62%

The nature of investing is that you win some, and you lose some. And unfortunately for Neuren Pharmaceuticals Limited (ASX:NEU) shareholders, the stock is a lot lower today than it was a year ago. In that relatively short period, the share price has plunged 62%. Even if you look out three years, the returns are still disappointing, with the share price down (the share price is down 49%) in that time. Furthermore, it’s down 16% in about a quarter. That’s not much fun for holders. This could be related to the recent financial results – you can catch up on the most recent data by reading our company report.

See our latest analysis for Neuren Pharmaceuticals

To quote Buffett, ‘Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace…’ One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.

Unhappily, Neuren Pharmaceuticals had to report a 13% decline in EPS over the last year. This reduction in EPS is not as bad as the 62% share price fall. Unsurprisingly, given the lack of EPS growth, the market seems to be more cautious about the stock.

You can see how EPS has changed over time in the image below (click on the chart to see the exact values).

ASX:NEU Past and Future Earnings, March 18th 2019
ASX:NEU Past and Future Earnings, March 18th 2019

It is of course excellent to see how Neuren Pharmaceuticals has grown profits over the years, but the future is more important for shareholders. It might be well worthwhile taking a look at our free report on how its financial position has changed over time.

A Different Perspective

While the broader market gained around 8.0% in the last year, Neuren Pharmaceuticals shareholders lost 62%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Unfortunately, last year’s performance may indicate unresolved challenges, given that it was worse than the annualised loss of 8.7% over the last half decade. We realise that Buffett has said investors should ‘buy when there is blood on the streets’, but we caution that investors should first be sure they are buying a high quality businesses. Most investors take the time to check the data on insider transactions. You can click here to see if insiders have been buying or selling.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on AU exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.